Study #2018-0576
A Phase II Trial to Evaluate Combination Therapy with Pemetrexed and Avelumab in Previously Treated Patients with MTAP-Deficient Advanced Urothelial Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
Avelumab, Pemetrexed
Description
This phase II trial studies how well pemetrexed and avelumab work in treating patients with MTAP-deficient urothelial cancer that has spread to other places in the body. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pemetrexed and avelumab may work better in treating patients with MTAP-deficient urothelial cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Metastatic Urothelial Carcinoma, MTAP Negative
Study phase:
Phase II
Physician name:
Amishi Shah
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-995-2744
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.